Tag

Semaglutide

All articles tagged with #semaglutide

health-and-science2 days ago•18 min saved

New Mouse and Human Data Suggest GLP-1 Drugs May Slow Biological Aging

New research indicates that GLP-1 medications, primarily used for weight loss and diabetes, may slow biological aging and extend lifespan. Studies on mice show semaglutide extends life beyond what is expected from calorie restriction alone, while human trials suggest tirzepatide and semaglutide reduce biological age by two to four years in various organs. Experts caution that these benefits are not yet proven for healthy, non-obese individuals.

via Yahoo Finance|

#anti-aging-research #eli-lilly #glp-1-drugs

health5 days ago•17 min saved

GLP-1 Side Effects: From Muscle Loss to Esophageal Rupture

As GLP-1 usage surges, experts warn of diverse side effects ranging from muscle and bone loss to rare esophageal ruptures. While common issues like nausea and hair loss are manageable with supplements and lifestyle changes, serious complications such as gallstones and Boerhaave syndrome require immediate medical attention. The WHO advises against prescribing these drugs to children under 10 due to insufficient safety data.

via HuffPost|

#glp-1 #health #ozempic

health5 days ago•6 min saved

GLP-1 Drugs May Slow Biological Aging by Up to Four Years, But Experts Cautious

New research suggests GLP-1 medications like tirzepatide and semaglutide may slow biological aging by two to six years, potentially extending lifespan. However, experts warn that benefits for healthy, non-obese individuals remain unproven, and it is unclear if effects stem from weight loss or the drugs themselves.

via CNN|

#anti-aging #biological-age #glp-1-drugs

health-and-science13 days ago•7 min saved

New Mouse Study Links Semaglutide to Slower Aging and Longer Lifespan

A new study in Nature demonstrates that semaglutide, a GLP-1 receptor agonist, slows aging and extends lifespan in female mice. While these drugs are approved for diabetes and obesity, emerging evidence suggests they offer broader therapeutic benefits beyond weight loss and glucose control, though the specific mechanisms remain unclear.

via Nature|

#aging-research #glp-1-agonists #health-and-science

health16 days ago•3 min saved

GLP-1 Drugs May Reduce Heavy Drinking, but Evidence on Cravings Remains Mixed

A new review in Biological Psychiatry suggests that GLP-1 receptor agonists, such as semaglutide, may help reduce heavy drinking days and overall alcohol intake for some individuals. However, the evidence is inconsistent regarding whether these drugs effectively reduce alcohol cravings. While clinical trials show promising results for reducing consumption, particularly in people with obesity, the data does not yet confirm a direct link to reduced cravings or establish the drugs as a standard treatment for alcohol use disorder.

via ScienceAlert|

#alcohol-use-disorder #clinical-trials #glp-1-agonists

health22 days ago•7 min saved

Yale Study Identifies Metformin and Semaglutide as Top Anti-Aging Interventions

A Yale University study published in Nature Medicine analyzes 51 human trials to determine which interventions actually lower biological age. The research confirms that lifestyle changes and specific prescription drugs, notably metformin and semaglutide, significantly reduce epigenetic age markers. In contrast, over-the-counter supplements and certain medical procedures showed minimal impact. While these biomarker shifts suggest a slowing of biological aging, researchers caution that a younger clock reading does not yet guarantee longer life or reduced disease risk.

via scitechdaily.com|

#anti-aging #biological-age #epigenetics

health23 days ago•5 min saved

Why Ozempic Results Vary: Biology, Behavior, and Post-Discontinuation Trends

GLP-1 weight-loss drugs produce highly variable results, with some users losing over 20% of body weight while others see minimal change. Factors include genetics, emotional eating patterns, and diabetes status. A new Cleveland Clinic study indicates that many patients maintain weight loss after stopping medication through alternative treatments.

via timesofindia.indiatimes.com|

#cleveland-clinic #glp-1-drugs #health

health28 days ago•1 min saved

Stopping GLP-1 Drugs Linked to Sharp Rise in Heart Attack and Stroke Risk

Recent studies indicate that discontinuing GLP-1 medications like Ozempic can lead to a rapid resurgence of cardiovascular risks, including heart attacks and strokes, alongside weight regain and metabolic deterioration. While many patients stop treatment due to side effects or cost, the abrupt halt in therapy may trigger inflammation and blood pressure spikes that elevate long-term health dangers.

via Axios|

#cardiovascular-health #glp-1 #health

health1 month ago•4 min saved

Debate at Brazilian Endocrinology Congress Questions If GLP-1 Therapy Should Be Lifelong

At the 37th Brazilian Congress of Endocrinology and Metabolism, experts debated whether GLP-1 receptor agonists should be lifelong treatments. While some argue indefinite use is necessary to prevent weight regain and maintain cardiometabolic benefits, others advocate for individualized tapering or discontinuation for patients who maintain weight through lifestyle changes. Recent data suggests these drugs primarily reduce fat while preserving muscle, though long-term safety and access remain critical concerns.

via Medscape|

#cbem-2026 #glp-1-receptor-agonists #health

health1 month ago•20 min saved

GLP-1 Weight Loss Drugs Linked to Rare, Fatal Brain Disorder

A new study links popular GLP-1 weight-loss drugs to a rare, potentially fatal brain disorder called Wernicke encephalopathy. The condition, caused by vitamin B1 deficiency, can lead to permanent brain damage or death if untreated. While the risk is low, experts urge clinicians to monitor patients for symptoms, especially those experiencing gastrointestinal issues or malnutrition.

via New York Post|

#glp-1 #health #semaglutide

health1 month ago•2 min saved

Tirzepatide Outperforms Semaglutide in Weight Loss but Carries Higher Risk of Serious Side Effects

A new meta-analysis of 41,381 adults with overweight or obesity found that tirzepatide produces significantly greater weight loss and better blood sugar control than semaglutide. However, this efficacy comes with a trade-off: patients on tirzepatide experienced serious adverse events at a rate of 5.7%, compared to 2.9% for those on semaglutide. While discontinuation rates due to side effects did not differ significantly between the two groups, the higher incidence of serious events suggests clinicians must carefully balance efficacy against safety profiles when prescribing incretin-based therapies.

via Medscape|

#clinical-trials #health #obesity-treatment

health1 month ago•10 min saved

Semaglutide Linked to Lower Psychiatric Events and Rising Prescriptions for Mental Illness

New observational data suggests higher doses of semaglutide are associated with reduced neuropsychiatric events independent of weight loss, while prescription rates for GLP-1 drugs among adults with serious mental illness have risen significantly since 2018.

via Nature|

#clinical-trials #glp-1-agonists #health

health1 month ago•3 min saved

Berkeley study links late-life semaglutide use to 12% lifespan boost in mice

A new study published in Nature shows that administering semaglutide, the active ingredient in Ozempic and Wegovy, to older female mice extends their median lifespan by approximately 12%. Researchers found that the drug not only mimics the benefits of calorie restriction but also offers additional improvements in memory, blood sugar regulation, and exploratory behavior. While the findings suggest GLP-1 agonists may slow biological aging, experts caution that human translation requires further clinical trials.

via New York Post|

#aging #glp-1 #health

health1 month ago•41 min saved

MASH Treatment Enters Personalized Era with Resmetirom and Semaglutide Approvals

Metabolic dysfunction-associated steatohepatitis (MASH) has shifted from a condition with no approved drugs to one with two accelerated approvals: the thyroid hormone receptor-β agonist resmetirom and the GLP-1 receptor agonist semaglutide. Published in Nature, a review by Gallage et al. highlights that MASH is not a single disease but a heterogeneous spectrum with distinct liver-centric and cardiometabolic phenotypes. This variability suggests that future treatments must be stratified and potentially combinatorial, targeting specific pathways like fibrogenesis, inflammation, or metabolic dysfunction rather than using a one-size-fits-all approach.

via Nature|

#health #hepatology #liver-disease

science1 month ago•10 min saved

Semaglutide Extends Mice Lifespan by 12% Beyond Calorie Restriction

A study in Nature shows that late-life semaglutide treatment in female mice extends lifespan by 12.4% and slows aging markers, with benefits exceeding those of simple calorie restriction.

via Nature|

#anti-aging #glp-1 #lifespan